(Q28304882)

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2013.12.016

Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of cardiomyopathies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2013.12.016

The ubiquitin-proteasome system: focus on the heart.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2013.12.016

The ubiquitin-proteasome system in cardiac dysfunction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2013.12.016

HECT and RING finger families of E3 ubiquitin ligases at a glance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2013.12.016

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2013.12.016

The ubiquitin-proteasome system in cardiomyopathies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2013.12.016

Role of the ubiquitin proteasome system in the heart

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2013.12.016

F-box and leucine-rich repeat protein 22 is a cardiac-enriched F-box protein that regulates sarcomeric protein turnover and is essential for maintenance of contractile function in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2013.12.016

Molecular architecture and assembly of the eukaryotic proteasome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2013.12.016

Proteasome inhibitors: an expanding army attacking a unique target

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2013.12.016

Illuminating the ubiquitin/proteasome system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2013.12.016

A transgenic mouse model of the ubiquitin/proteasome system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2013.12.016

A novel transgenic mouse model reveals deregulation of the ubiquitin-proteasome system in the heart by doxorubicin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2013.12.016

Monitoring the ubiquitin/proteasome system in conformational diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2013.12.016

The ubiquitin proteasome system in neurodegenerative diseases: sometimes the chicken, sometimes the egg.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2013.12.016

Hyperubiquitination of proteins in dilated cardiomyopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2013.12.016

Myocytes die by multiple mechanisms in failing human hearts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2013.12.016

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2013.12.016

Protein aggregates and novel presenilin gene variants in idiopathic dilated cardiomyopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2013.12.016

Elevated p53 expression is associated with dysregulation of the ubiquitin-proteasome system in dilated cardiomyopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2013.12.016

Ubiquitin proteasome dysfunction in human hypertrophic and dilated cardiomyopathies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2013.12.016

TWIST1 regulates the activity of ubiquitin proteasome system via the miR-199/214 cluster in human end-stage dilated cardiomyopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2013.12.016

Classification of the cardiomyopathies: a position statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial Diseases.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2013.12.016

2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2013.12.016

Mechanisms of disease: hypertrophic cardiomyopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2013.12.016

Cardiac myosin-binding protein C in hypertrophic cardiomyopathy: mechanisms and therapeutic opportunities

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2013.12.016

Evidence for FHL1 as a novel disease gene for isolated hypertrophic cardiomyopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2013.12.016

COOH-terminal truncated cardiac myosin-binding protein C mutants resulting from familial hypertrophic cardiomyopathy mutations exhibit altered expression and/or incorporation in fetal rat cardiomyocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2013.12.016

Impairment of the ubiquitin-proteasome system by truncated cardiac myosin binding protein C mutants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2013.12.016

Atrogin-1 and MuRF1 regulate cardiac MyBP-C levels via different mechanisms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2013.12.016

Ubiquitin-proteasome system impairment caused by a missense cardiac myosin-binding protein C mutation and associated with cardiac dysfunction in hypertrophic cardiomyopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2013.12.016

Impairment of ubiquitin-proteasome system by E334K cMyBPC modifies channel proteins, leading to electrophysiological dysfunction.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2013.12.016

Nonsense-mediated mRNA decay and ubiquitin-proteasome system regulate cardiac myosin-binding protein C mutant levels in cardiomyopathic mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2013.12.016

Increased myofilament Ca2+ sensitivity and diastolic dysfunction as early consequences of Mybpc3 mutation in heterozygous knock-in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2013.12.016

Asymmetric septal hypertrophy in heterozygous cMyBP-C null mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2013.12.016

Defective proteolytic systems in Mybpc3-targeted mice with cardiac hypertrophy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2013.12.016

Adrenergic stress reveals septal hypertrophy and proteasome impairment in heterozygous Mybpc3-targeted knock-in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2013.12.016

Impact of ANKRD1 mutations associated with hypertrophic cardiomyopathy on contraction parameters of engineered heart tissue.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2013.12.016

Cooperative control of striated muscle mass and metabolism by MuRF1 and MuRF2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2013.12.016

Human molecular genetic and functional studies identify TRIM63, encoding Muscle RING Finger Protein 1, as a novel gene for human hypertrophic cardiomyopathy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2013.12.016

Genetic mutations and mechanisms in dilated cardiomyopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2013.12.016

Truncations of titin causing dilated cardiomyopathy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2013.12.016

A missense mutation in the alphaB-crystallin chaperone gene causes a desmin-related myopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2013.12.016

Tragedy in a heartbeat: malfunctioning desmin causes skeletal and cardiac muscle disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2013.12.016

Expression of R120G-alphaB-crystallin causes aberrant desmin and alphaB-crystallin aggregation and cardiomyopathy in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2013.12.016

Intrasarcoplasmic amyloidosis impairs proteolytic function of proteasomes in cardiomyocytes by compromising substrate uptake

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2013.12.016

Mouse model of desmin-related cardiomyopathy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2013.12.016

'State-of-the-heart' of cardiac laminopathies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2013.12.016

Heterozygous LmnadelK32 mice develop dilated cardiomyopathy through a combined pathomechanism of haploinsufficiency and peptide toxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2013.12.016

Functional characterization of a novel mutation in NKX2-5 associated with congenital heart disease and adult-onset cardiomyopathy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2013.12.016

Whole-genome analysis of gene expression associates the ubiquitin-proteasome system with the cardiomyopathy phenotype in disease-sensitized congenic mouse strains

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2013.12.016

The ubiquitin-proteasome system and nonsense-mediated mRNA decay in hypertrophic cardiomyopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2013.12.016

How do MYBPC3 mutations cause hypertrophic cardiomyopathy?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2013.12.016

Cardiac myosin-binding protein C mutations and hypertrophic cardiomyopathy: haploinsufficiency, deranged phosphorylation, and cardiomyocyte dysfunction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2013.12.016

Contractile dysfunction irrespective of the mutant protein in human hypertrophic cardiomyopathy with normal systolic function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2013.12.016

Reversible cytoplasmic localization of the proteasome in quiescent yeast cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2013.12.016

Aggresomes, inclusion bodies and protein aggregation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2013.12.016

Aberrant protein aggregation is essential for a mutant desmin to impair the proteolytic function of the ubiquitin-proteasome system in cardiomyocytes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2013.12.016

Mitochondrial free radical generation, oxidative stress, and aging

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2013.12.016

Degradation of oxidized proteins by the 20S proteasome.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2013.12.016

Differential regulation of proteasome function in isoproterenol-induced cardiac hypertrophy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2013.12.016

Impaired assembly and post-translational regulation of 26S proteasome in human end-stage heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2013.12.016

Revealing the dynamics of the 20 S proteasome phosphoproteome: a combined CID and electron transfer dissociation approach

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2013.12.016

PKA rapidly enhances proteasome assembly and activity in in vivo canine hearts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2013.12.016

What is the role of beta-adrenergic signaling in heart failure?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2013.12.016

Beta-adrenergic signaling in heart failure-adapt or die.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2013.12.016

Alterations in cAMP-mediated signaling and their role in the pathophysiology of dilated cardiomyopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2013.12.016

Perturbed length-dependent activation in human hypertrophic cardiomyopathy with missense sarcomeric gene mutations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2013.12.016

Decreased phosphorylation levels of cardiac myosin-binding protein-C in human and experimental heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2013.12.016

Cardiac myosin binding protein C phosphorylation in cardiac disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2013.12.016

Ozz-E3, a muscle-specific ubiquitin ligase, regulates beta-catenin degradation during myogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2013.12.016

Atrogin-1/muscle atrophy F-box inhibits calcineurin-dependent cardiac hypertrophy by participating in an SCF ubiquitin ligase complex

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2013.12.016

Mdm2 promotes the rapid degradation of p53

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2013.12.016

Proteasome functional insufficiency activates the calcineurin-NFAT pathway in cardiomyocytes and promotes maladaptive remodelling of stressed mouse hearts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2013.12.016

Biology of endoplasmic reticulum stress in the heart

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2013.12.016

The unfolded protein response at the crossroads of cellular life and death during endoplasmic reticulum stress.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2013.12.016

Overexpression of endoplasmic reticulum-resident chaperone attenuates cardiomyocyte death induced by proteasome inhibition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2013.12.016

Autophagy in the Pathogenesis of Disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2013.12.016

Sorting, recognition and activation of the misfolded protein degradation pathways through macroautophagy and the proteasome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2013.12.016

Autophagy: links with the proteasome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2013.12.016

Autophagy and p62 in cardiac proteinopathy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2013.12.016

Activation of the cardiac proteasome during pressure overload promotes ventricular hypertrophy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2013.12.016

Suppression of cardiomyocyte hypertrophy by inhibition of the ubiquitin-proteasome system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2013.12.016

Proteasome inhibition decreases cardiac remodeling after initiation of pressure overload

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2013.12.016

Proteasome inhibition promotes regression of left ventricular hypertrophy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2013.12.016

Primary proteasome inhibition results in cardiac dysfunction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2013.12.016

Unexpected cardiotoxicity in haematological bortezomib treated patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2013.12.016

Acute severe cardiac failure in a myeloma patient due to proteasome inhibitor bortezomib

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2013.12.016

Severe heart failure after bortezomib treatment in a patient with multiple myeloma: a case report and review of the literature

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2013.12.016

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2013.12.016

Inhibiting Hdm2 and ubiquitin-activating enzyme: targeting the ubiquitin conjugating system in cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2013.12.016

Protein kinase CK2 links extracellular growth factor signaling with the control of p27Kip1 stability in the heart

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2013.12.016

Specific small molecule inhibitors of Skp2-mediated p27 degradation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2013.12.016

Depression of proteasome activities during the progression of cardiac dysfunction in pressure-overloaded heart of mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2013.12.016

Enhancement of proteasomal function protects against cardiac proteinopathy and ischemia/reperfusion injury in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2013.12.016

Enhancement of proteasome activity by a small-molecule inhibitor of USP14

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2013.12.016

Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2013.12.016

PDE5 inhibition with sildenafil improves left ventricular diastolic function, cardiac geometry, and clinical status in patients with stable systolic heart failure: results of a 1-year, prospective, randomized, placebo-controlled study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2013.12.016

Sildenafil and B-type natriuretic peptide acutely phosphorylate titin and improve diastolic distensibility in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2013.12.016

Protein kinase g positively regulates proteasome-mediated degradation of misfolded proteins.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2013.12.016